USFDA approval for Orchid
By Our Corporate Bureau | 05 Dec 2003
Chennai: Orchid Chemicals & Pharmaceuticals, a city-based bulk drug major, has formally received the approval from the United States Food and Drugs Administration (USFDA) for its sterile API (active pharmaceutical ingredient) product Cefazolin.
The USFDA authorities inspected the plant this September. An important sterile cephalosporin antibiotic API, Cefazolin is used in the treatment of several infections. Orchid has established world-class sterile lyophilisation and non-sterile facilities for integrated manufacture of this product.
"This is definitely a very key development for Orchid and another significant milestone in our regulatory roadmap. This approval will enable a strong entry for our sterile injectable product, Cefazolin, into the US market. We hope to start exports of this product to the US soon," says Orchid managing director Raghavendra Rao.
Latest articles
Featured articles
The New Oil (Part 4): Can Technology Break the Dependency?
By Cygnus | 16 Jan 2026
Can magnet recycling and rare-earth-free motors reduce global dependence on strategic minerals? Part 4 explores breakthroughs, limits and timelines.
India’s Gig Economy Reset: The End of ‘10-Minute Delivery’ Hype?
By Cygnus | 14 Jan 2026
India’s quick-commerce sector is shifting away from “10-minute delivery” hype amid worker safety concerns and rising regulation. Here’s what changes—and what doesn’t.
AI Is Becoming the New Electricity Crisis: Why the Real Bottleneck Is Megawatts
By Axel Miller | 14 Jan 2026
AI is turning into an electricity crisis as data centres scale from chips to megawatts. Grid bottlenecks, copper demand and cooling limits are now the real AI constraints.
The New Oil: Can Technology End the Rare Earth Dependency?
By Cygnus | 14 Jan 2026
Magnet recycling and rare-earth-free motors are emerging as technology escape routes from critical mineral dependency. But timelines are slower than the hype suggests.
The New Oil: Inside the Processing Gap — Why Mining Alone Won’t Fix the Critical Minerals Crisis
By Cygnus | 13 Jan 2026
Mining isn’t the real bottleneck in critical minerals. The 2026 processing gap — refining, separation and chemical conversion — is the chokepoint reshaping global supply chains, industrial policy and geopolitics.
The Battle for the Skies: Air India’s Widebody Bet vs IndiGo’s XLR Gambit
By Cygnus | 12 Jan 2026
Air India vs IndiGo fleet strategy 2026: Air India expands with new Boeing 787-9 widebodies while IndiGo uses A321XLR efficiency and IndiGoStretch to reshape long-haul economics.
The Custom Dreamliner: Air India Reclaims Its Skies with First Post-Privatisation 787-9
By Axel Miller | 12 Jan 2026
Air India’s comeback under Tata enters a new phase as its first post-privatisation custom Dreamliner strengthens the fleet renewal push for premium long-haul travel.
The New Oil: How the 2026 lithium and graphite bottleneck could stall global EV growth
By Cygnus | 12 Jan 2026
Lithium and graphite are emerging as the key EV bottlenecks in 2026 as South America expands mining while China dominates processing and battery-grade conversion.
The New Oil: How the 2026 Rare Earth Shock Is Reshaping the Global Economy
By Cygnus | 09 Jan 2026
Japan launches a 6,000m deep-sea mission as China restricts rare earth exports. Discover how the 2026 “New Oil” crisis is redefining global high-tech trade.
Business History Videos
History of hovercraft Part 3...
Today I shall talk a bit more about the military plans for ...
By Kiron Kasbekar | Presenter: Kiron Kasbekar
History of hovercraft Part 2...
In this episode of our history of hovercraft, we shall exam...
By Kiron Kasbekar | Presenter: Kiron Kasbekar
History of Hovercraft Part 1...
If you’ve been a James Bond movie fan, you may recall seein...
By Kiron Kasbekar | Presenter: Kiron Kasbekar
History of Trams in India | ...
The video I am presenting to you is based on a script writt...
By Aniket Gupta | Presenter: Sheetal Gaikwad
view more
